Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.420
-0.450 (-9.24%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $251.15K in the quarter ending March 31, 2026, a decrease of -2.61%. This brings the company's revenue in the last twelve months to $7.94M, up 115.44% year-over-year. In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth.
Revenue (ttm)
$7.94M
Revenue Growth
+115.44%
P/S Ratio
13.06
Revenue / Employee
$992,377
Employees
8
Market Cap
103.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Verrica Pharmaceuticals | 37.16M |
| Alpha Cognition | 10.83M |
| Alps Group | 3.74M |
| Kazia Therapeutics | 1.27M |
| NeOnc Technologies Holdings | 39.99K |
| Fractyl Health | 3.00K |
COYA News
- 1 day ago - Coya Therapeutics initiated with a Buy at Roth Capital - TheFly
- 10 days ago - Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit - Business Wire
- 24 days ago - Coya Therapeutics Proxy statement: Proxy filing - Filings
- 24 days ago - Coya Therapeutics Proxy statement: Proxy filing - Filings
- 25 days ago - Coya Therapeutics granted FDA Fast Track Designation for COYA 302 - TheFly
- 25 days ago - Coya Therapeutics reports Q1 EPS (32c), consensus (39c) - TheFly
- 25 days ago - Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
- 25 days ago - Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire